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Abstract
Background: Previous research suggests that novel biomarkers may be used to identify patients at increased risk of
acute kidney injury following cardiac surgery. The purpose of this study was to evaluate the relationship between
preoperative levels of circulating Galectin-3 (Gal-3) and acute kidney injury after cardiac surgery.
Methods: Preoperative serum Gal-3 was measured in 1498 patients who underwent coronary artery bypass graft
(CABG) surgery and/or valve surgery as part of the Northern New England Biomarker Study between 2004 and
2007. Preoperative Gal-3 levels were measured using multiplex assays and grouped into terciles. Univariate and
multinomial logistic regression was used to assess the predictive ability of Gal-3 terciles and AKI occurrence and
severity.
Results: Before adjustment, patients in the highest tercile of Gal-3 had a 2.86-greater odds of developing
postoperative KDIGO Stage 2 or 3 (p < 0.001) and 1.70-greater odds of developing KDIGO Stage 1 (p = < 0.001),
compared to the first tercile. After adjustment, patients in the highest tercile had 2.95-greater odds of developing
KDIGO Stage 2 or 3 (p < 0.001) and 1.71-increased odds of developing KDIGO Stage 1 (p = 0.001), compared to the
first tercile. Compared to the base model, the addition of Gal-3 terciles improved discriminatory power compared
to without Gal-3 terciles (test of equality = 0.042).
Conclusion: Elevated preoperative Gal-3 levels significantly improves predictive ability over existing clinical models
for postoperative AKI and may be used to augment risk information for patients at the highest risk of developing
AKI and AKI severity after cardiac surgery.
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Background
Acute kidney injury (AKI) is a well recognized complica-
tion following cardiac surgery, and significantly affects
morbidity and mortality [1, 2]. Up to 40% of patients de-
velop AKI after cardiac surgery and places patients at
5-fold higher risk of death during hospitalization [3].
AKI has also been associated with hospital readmissions
following cardiac surgery and hospitalization for heart
failure or acute myocardial infarction (MI) [4–8].
Conventional metrics used to define and monitor the
progression of AKI, such as serum creatinine and blood
urea nitrogen levels, are insensitive, nonspecific and
change notably only after significant kidney injury [8].
Identifying patients at increased risk of AKI prior to surgery
is critical to take preventative measures and counsel
patients on potential outcomes after cardiac surgery. A
timely diagnosis would allow for earlier clinical interven-
tion, greater care management prior to surgery, improved
patient engagement and could improve patient outcomes.
New biomarkers allow a diagnosis to be made earlier
than conventional measures, and allows kidney injury to
be diagnosed even in the absence of concurrent or sub-
sequent dysfunction. Biomarkers have been utilized to
* Correspondence: jbrown@dartmouth.edu; jeremiah.r.brown@dartmouth.edu
6The Dartmouth Institute for Health Policy and Clinical Practice, Geisel School
of Medicine, Lebanon, NH, USA
8Department of Biomedical Data Science, HB 7505 Dartmouth-Hitchcock
Medical Center, Lebanon, NH NH 03756, USA
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Wyler von Ballmoos et al. BMC Nephrology          (2018) 19:280 
https://doi.org/10.1186/s12882-018-1093-0
investigate AKI and augment the prediction of AKI risk
and other complications following cardiac surgery [9–
12]. A specific and sensitive marker of AKI risk could
improve risk stratification, potentially identify patients
that will benefit from greater care management prior to
surgery and alert clinicians to individuals that will need
earlier interventions to prevent AKI. Current risk predic-
tion models for AKI following cardiac surgery have been
developed on patient and disease characteristics alone.
The addition of a specific protein biomarker may im-
prove predictive ability over existing clinical models and
may augment risk information for patients at higher risk
of AKI after surgery.
Galectin-3 (Gal-3) is a beta-galactoside-binding lectin
that has emerged as a key regulator of inflammation and
tissue fibrosis [13]. Experimental studies in models of
cancer, congestive heart failure and inflammatory disease
have demonstrated that Gal-3 expression is elevated in
these pathologic conditions [9]. In animal models, Gal-3
is acutely up-regulated in the kidneys in response to is-
chemic and toxic injury and is associated with renal fi-
brosis [14–17]. In humans, elevated levels of circulating
Gal-3 have been found to be associated with increased
risk of incident chronic kidney disease (CKD) and loss of
kidney function over time [11, 18]. Gal-3 therefore can
be considered a marker of both acute and chronic in-
flammatory processes in the kidneys, even in the absence
of traditional clinical markers of renal injury.
There is an urgent need to analyze the predictive util-
ity of Gal-3 to identify patients at greater risk of devel-
oping postoperative AKI. To date, Gal-3 has not been
investigated as a potential biomarker for AKI in humans.
The purpose of this study was to evaluate the assocation
between preoperative Gal-3 and postoperative AKI in a
large cohort of cardiac surgical patients.
Methods
NNE biomarker study
This study expands on the experience of Northern New
England Cardiovascular Disease Study Group
(NNECDSG), a regional collaborative consortium founded
in 1987. All eight hospitals in this consortium submit data
on cases with validation of procedure numbers and mor-
tality conducted every 2 years. The NNECDSG registry
contains data on patient characteristics, procedural indica-
tions, clinical variables and in-hospital outcomes. Data are
periodically validated to ensure that all procedures and
endpoints included in the registry have been accurately
assessed. The NNECDSG has extensive experience in risk
prediction in CABG surgery [4, 5]. The Northern New
England (NNE) Biomarker Study is an initiative designed
to assess the role of biomarkers in cardiac surgery.
Patient, procedural and outcome data were collected
from patients undergoing coronary CABG surgery.
Those undergoing CABG incidental to heart valve repair
or replacement, resection of a ventricular aneurysm, or
other surgical procedure were not included. Only pa-
tients that had biomarker levels collected were retained
in the final analyses (n = 1498). For the present study,
the sample included patients undergoing emergent, ur-
gent and non-urgent CABG surgeries. Investigators and
patients were blinded to the collected biomarker levels.
The Committee for the Protection of Human Subjects at
Dartmouth College (Institutional Review Board) ap-
proved this study for both the prospective cohort with
patient consent and the linkage of readmission and mor-
tality events.
Galectin-3
Preoperative levels of Gal-3 was the main exposure of
interest for this study. Blood samples were preopera-
tively collected prior to incision at each participating site
in a 10-mL serum tube. Preoperative biomarker levels
were measured using custom made multiplex ELISA as-
says (Meso Scale Discovery, Rockville, MD). Blood was
allowed to clot at room temperature for 20 min to separ-
ate out the red blood cells, the tubes were centrifuged at
3500 rpm for 20 min, and the sera stored at the respect-
ive medical centers below − 80 degree Celcius until
transportation on dry ice to the Laboratory for Clinical
and Biomedical Research in Colchester, Vermont where
they were stored at − 80 degree Celcius until measure-
ment. Frozen serum was analyzed at a central laboratory,
at the same time for biomarker measurement. Bio-
markers were linked to the NNECDSG cohort to con-
duct the preoperative risk prediction modeling.
Biomarkers were evaluated as continuous variables, nat-
ural log-transformed, and as terciles.
Acute kidney injury
The primary outcome of this study was the development
of AKI after cardiac surgery. The last serum creatinine
(SCr) prior to cardiac surgery and highest postoperative
SCr prior to discharge were used to classify the stage of
AKI. AKI stages were defined by the Kidney Disease: Im-
proving Global Outcomes (KDIGO) definition as follows
[19]: Stage 1: increase in SCr by > 0.3 mg/dL within 48 h
or > 1.5 times baseline within 7 days; Stage 2: increase in
SCr to 2 to 2.9-fold baseline; and Stage 3: increase in
SCr to 3.0 times baseline or increase in SCr to > 4.0 mg/
dL or initiation of renal replacement therapy. Due to the
small proportion of patients in KDIGO stage 2 and 3,
we bundled stage 2 or 3 patients’ outcomes in this
report.
Statistical analysis
We evaluated the Gal-3 measurements to determine the
association with the primary outcome (AKI) using
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univariate and multinomial logistic regression. Postoper-
ative outcomes were compared using chi-squared tests,
and continuous data were compared using the ANOVA
test with the Bonferroni correction. Adjustment was car-
ried out using variables from the Society of Thoracic
Surgeons (STS) readmission model (Appendix) [20].To
evaluate the association of the biomarker with AKI
outcomes, we divided the cohort into terciles on the
basis of Gal-3 values, where the lowest tercile is the
reference group. We included indicator variables for
the middle and highest terciles. We applied the mean
imputation replacement method to account for vari-
ables with missing values. All biomarker values below
the assay’s lower quantitative limit were assigned the
lower limit of detection. The performance of the risk
model was assessed by measuring the total area under
the receiver operating characteristic curve (AUC or
c-statistic). Standard errors and 95% confidence inter-
vals were estimated for the c-statistic using a boot-
strap method. All analyses were conducted using
Stata 13.1 College Station, TX).
Secondary Analyes
We compared the incremental value of Gal-3 to pre-
operative eGFR, a traditional risk marker of AKI. We
adjusted the model using the STS readmission model
and used the test of equality of ROC areas to assess
differences in model performance. We calculated the
Net Reclassification Improvement (NRI) and Inte-
grated Discrimination Improvement (IDI) indices for
risk models including Gal-3 and eGFR values.
Finally, we also created an alternative final model
including both preoperative N-terminal pro b-type
natriuretic peptide (NT-proBNP) values and preopera-
tive Gal-3, in addition to the base STS readmission
prediction model, to assess the predictive power using
a combination of biomarkers. We compared model
performance using the test of equality of ROC areas.
Results
Overall, 1489 patients were included in the study. 481
(32.1%) developed AKI within KDIGO Stage 1 (26.3%)
and 87 (5.8%) experienced KDIGO Stage 2 or 3 (Fig. 1).
Patient and procedural characteristics are summarized in
Table 1. Patient and procedural characteristics and the
association with Gal-3 tercile measurements are summa-
rized in Table 2. Gal-3 sample measurements ranged
from 1.38 to 102.35 ng/mL with a median (Q1, Q3)
value of 10.30 ng/mL (6.96 to 14.67 ng/mL).
Among patients studied, there was a significant dif-
ference between postoperative AKI incidence for older
patients and patients with a higher BMI, history of
smoking, atrial fibrillation, congrestive heart failure
(CHF), diabetes, ejection fraction < 40, prior MI, vas-
cular disease, received transfused blood, and red
blood cells transfused postoperatively. There is a
significant relationship between elevated Gal-3 mea-
surements and increased AKI severity (p < 0.001). For
patients in the lowest tercile of Gal-3, 22.9% experi-
enced KDIGO Stage 1 compared to 31.6% in the
highest biomarker tercile. Similarly, for patients in the
highest Gal-3 tercile, 1.8% of patients experienced
KDIGO Stage 3 compared to 1.2% in the lowest
tercile.
Table 3 describes the unadjusted and adjusted results
for the AKI risk model and Gal-3 biomarker terciles. Be-
fore adjustment, patients in the highest tercile of Gal-3
had a 2.86-greater odds of developing postoperative
KDIGO Stage 2 or 3 AKI (p < 0.001) and 1.70-greater
odds of developing KDIGO Stage 1 (p < 0.001). After
adjustment, patients in the highest tercile had
2.95-greater odds of developing KDIGO Stage 2 or 3
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Fig. 1 Association of preoperative Galectin-3 and postoperative AKI severity after coronary artery bypass graft surgery, by Galectin-3 tercile. The
mean Galectin-3 measurement for each tercile increases stepwise with postoperative AKI severity. There is a significant relationship between
elevated preoperative Galectin-3 and AKI severity by KDIGO
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(p < 0.001) and 1.71-increased odds of developing
KDIGO Stage 1 (p = 0.001). When preoperative levels of
NT-proBNP were added to the risk prediction model,
we observed similar results. Patients in the highest ter-
cile of Gal-3 had 2.85-greater odds of developing
KDIGO Stage 2 or 3 AKI (p = 0.001) and patients in the
lowest tercile at 1.65-greater odds of KDIGO Stage 1
AKI (p = 0.003).
The base and augmented models are summarized in
Table 4. The base model yieled a c-statistic of 0.69 (95%
CI: 0.66–0.71). The base model with the addition of pre-
operative Gal-3 terciles yielded a c-statistic of 0.70 (95%
CI: 0.67–0.72) and has a significant ROCCOMP p value
of 0.042 compared to the base model alone. With the
addition of Gal-3 and NT-proBNP terciles to the base
model, the c-statistic remains at 0.70 (95% CI: 0.68 0.73)
and is significantly improved from the base model alone
(ROCCOMP p value = 0.005).
In an exploratory analysis where we compared pre-
operative Gal-3 terciles to preoperative eGFR values, we
did not find an appreciable difference between the two
makers and risk of developing AKI. Models comparing
preoperative Gal-3 tercile values to continuous eGFR
values are reported in Table 5.
Discussion
We are the first to demonstrate a significant relation-
ship between the inflammatory biomarker Gal-3 and
AKI in a multi-site, prospectively enrolled cohort of
patients undergoing cardiac surgery. We found Gal-3
concentrations increased concurrently with decreasing
kidney function. In our study, patients in the highest
tercile of preoperative Gal-3 levels had 1.7 times the
adjusted odds of KDIGO Stage 1 AKI compared to
patients in the lowest tercile of Gal-3. Patients in the
highest tercile of preoperative Gal-3 also had 2.9
times the adjusted odds of KDIGO Stage 2 or 3 AKI
compared to the lowest tercile.
Gal-3 is a well-established biomarker for cardiac fibro-
sis, ventricular dysfunction, and poor prognosis in heart
failure [21–23]. In addition, Gal-3 has demonstrated
diagnostic and prognostic value in diseases of the kidney
[9, 11, 18]. Drechsler et al. found a positive association
between elevated levels of Gal-3 and adverse outcomes
in patients with preexisting renal disease. Additionally,
in the well recognized Framingham Heart Study, re-
searchers demonstrated that elevated Gal-3 levels pre-
cede the development of CKD [10, 11]. Prior to our
analysis, studies examining the relationship between
Gal-3 and acute renal injury after surgery had been lim-
ited to animal models. Multiple animal studies have
demonstrated that Gal-3 expression is up-regulated in
the kidneys in response to ischemic and toxic injury and
is associated with renal fibrosis [14–17].
Table 1 Patient and procedural characteristics and
postoperative AKI occurrence
No AKI
(N = 1017)
AKI
(N = 481)
p value
Age* 64.02 ± 9.99 68.08 ± 9.90 0.000
Female 23.8% 23.0% 0.740
BMI* 29.22 ± 5.17 30.35 ± 6.07 0.000
BSA* 2.03 ± 0.24 2.04 ± 0.26 0.200
Smoker 26.1% 16.6% 0.000
Atrial fibrillation 5.2% 9.3% 0.003
CHF 8.4% 13.5% 0.002
Pre-operative creatinine* 1.08 ± 1.02 1.15 ± 0.43 0.108
Diabetes 32.8% 43.3% 0.000
EF < 40 8.9% 14.0% 0.003
Hypertension 80.2% 81.7% 0.503
Pre-operative IABP 3.2% 5.7% 0.019
Prior MI 0.004
None 59.7% 49.8%
< 24 h preop 1.5% 1.9%
> 24 h & < 7 days 17.7% 21.9%
> 7 & < 365 days 8.4% 12.5%
> 365 days 12.7% 13.9%
VAD 24.5% 32.5% 0.001
Unstable angina 55.3% 56.0% 0.780
COPD 12.4% 14.3% 0.321
LM stenosis 33.3% 35.0% 0.520
Prior CABG 1.8% 3.3% 0.064
Prior PCI 20.3% 18.4% 0.396
Priority 0.297
Emergency or emergent salvage 1.5% 2.7%
Urgent 67.6% 67.9%
Non-urgent 30.9% 29.5%
Received transfused blood 29.1% 54.9% 0.000
pRBCs transfused pre-operatively 0.385
0 98.5% 97.3%
1 0.4% 1.0%
2 0.7% 1.3%
3 or more 0.4% 0.4%
pRBCs transfused
post-operatively
0.000
0 77.8% 57.9%
1 5.9% 9.1%
2 10.7% 16.8%
3 or more 5.7% 16.2%
Pump time (mean, SD) 100.88 ± 32.01 112.44 ± 37.43 0.000
AKI acute kidney injury, BMI body mass index (kg/m2), BSA body surface
area (m2), CABG coronary artery bypass graft, CHF congestive heart
failure, COPD chronic obstructive pulmonary disease, IABP intra-operative
balloon pump, MI myocardial infarction, PCI percutaneous coronary
intervention, RBC red blood cell, SD standard deviation
*signifies continuous variables
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In the kidney, Gal-3 has multiple functions includ-
ing regulating the inflammatory response and cell
growth, proliferation, and differentiation [24, 25].
Gal-3 has been proposed to be a marker of com-
bined cardiac and renal fibrosis in the chronic
setting [24, 25]. The prognostic value of baseline im-
paired cardiac and renal functional reserve may pre-
dict risk of AKI after cardiac surgery [26]. A 15%
change from baseline has been associated with
significantly more heart failure hospitalizations and
Table 2 Patient and procedural characteristics and association with Gal-3 terciles
Patient characteristics Overall 1st Tercile 2nd Tercile 3rd Tercile p value
KDIGO
No AKI 67.9% 73.4% 70.5% 59.6% < 0.001
Stage 1 26.3% 22.9% 24.6% 31.6%
Stage 2 4.5% 2.6% 4.2% 6.9%
Stage 3 1.3% 1.2% 0.8% 1.8%
Agea 65.7 ± 9.9 63.6 ± 10.0 65.5 ± 9.6 66.8 ± 10.6 0.464
Female 22.7% 18.2% 20.6% 32.0% < 0.001
BMIa 29.6 ± 5.5 29.6 ± 5.2 29.6 ± 5.5 29.8 ± 5.9 0.464
BSAa 2.0 ± 0.2 2.0 ± 0.3 2.1 ± 0.2 2.0 ± 0.3 0.464
Smoker 21.4% 24.4% 22.2% 21.4% 0.488
Atrial fibrillation 6.5% 5.4% 6.2% 8.7% 0.082
CHF 11.2% 7.3% 8.7% 15.9% < 0.001
Last pre-op serum creatinine (mean, SD) 1.1 ± 0.6 1.1 ± 0.5 1.1 ± 1.4 1.3 ± 1.0 0.464
Diabetes 38.0% 34.6% 33.9% 43.8% 0.001
Ejection fraction < 40% 12.1% 10.6% 10.0% 12.3% 0.508
Hypertension 81.0% 79.2% 80.1% 83.0% 0.273
IABP pre-op 3.8% 4.6% 4.8% 2.7% 0.165
Prior MI
No 54.6% 57.3% 57.4% 53.7% 0.098
< 24 h pre-op 1.5% 1.4% 1.5% 2.1%
> 24 h & < 7 days pre-op 20.5% 18.7% 19.6% 18.0%
> 7 days & < 365 days pre-op 9.8% 7.9% 8.45% 13.6%
> 365 days pre-op 13.6% 14.7% 12.7% 12.6%
Vascular disease 27.8% 26.1% 25.2% 30.2% 0.154
Unstable angina 58.2% 53.7% 55.0% 58.1% 0.347
COPD 12.6% 11.2% 12.1% 15.5% 0.095
Left main, ≥50% stenosis 31.5% 33.0% 35.3% 33.0% 0.669
Prior CABG 2.4% 2.3% 2.8% 1.8% 0.566
Prior PCI 19.6% 20.5% 18.7% 20.0% 0.760
Priority
Emergent 1.5% 2.5% 1.7% 1.6% 0.815
Urgent 70.1% 68.0% 67.4% 67.8%
Non-urgent 28.3% 29.5% 30.8% 30.6%
Received pRBC units 30.4% 35.5% 48.6% < 0.001
Number of pRBC units given pre-op
0 97.9% 99.4% 97.5% 97.1% 0.142
1 or more 2.1% 0.6% 2.5% 2.9%
a(Mean, SD)
AKI acute kidney injury, KDIGO Kidney Disease: Improving Global Outcomes, BMI, body mass index (kg/m2), BSA body surface area (m2), CABG coronary artery
bypass graft, CHF congestive heart failure, COPD chronic obstructive pulmonary disease, IABP intra-operative balloon pump, MI myocardial infarction, PCI
percutaneous coronary intervention, RBC red blood cell, SD standard deviation
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increased mortality compared with lower and decreasing
levels [21]. In addition, Gal-3 has been shown to stimulate
macrophages to release pro-inflammatory cytokines (e.g.
MCP-1, IL-6, and IL-1B) and produce reactive oxygen
species, enhancing the inflammatory response in the kid-
ney [17]. Knocking-out the Gal-3 gene or directly
inhibiting the Gal-3 protein is known to inhibit renal fi-
brosis and lessen renal injury in AKI [16, 27, 28].
We have demonstrated that preoperative levels of
circulating Gal-3 are associated with AKI and AKI se-
verity after cardiac surgery. Patients with higher levels
of circulating Gal-3 may be predisposed to excessive
inflammatory processes. Preoperative Gal-3 levels
could also be acting as a marker for early CKD, iden-
tifying patients more susceptible to AKI because of
underlying kidney disease. Further, preoperative Gal-3
may be serving as an indicator of heart failure (HF)
and those patients at risk of AKI due to ischemic
renal injury secondary to pump failure. Preoperative
measurement of Gal-3 may provide a means to evalu-
ate AKI risk due to multiple etiologies.
Multiple preoperative biomarkers have been evalu-
ated for their ability to predict AKI after cardiac sur-
gery. Cystatin C (CysC) is a circulating protease
inhibitor and correlates with the glomerular filtration
Table 4 Model comparison statistics evaluating the
discriminatory power of the base regression model and the
additive value of preoperative Gal-3 terciles and preoperative
NT-proBNP terciles
C-statistic (95% CI) ROCCOMP
p valuea
STS Readmission Prediction Model 0.69 (0.66–0.71)
STS model + Gal-3 preoperative terciles 0.70 (0.67–0.72) 0.042
STS model + combined Gal-3 and
NT-pro BNP preoperative terciles
0.70 (0.68–0.73) 0.005
aROC comparison against base model
Table 3 Unadjusted and STS adjusted model evaluating preoperative Gal-3 measurements and association with KDIGO stage
severity
KDIGO Stage 1 KDIGO Stage 2 or 3
OR 95% CI p value OR 95% CI p value
Unadjusted
Preoperative 1.03 1.01–1.04 0.000 1.04 1.02–1.06 0.000
Natural log 1.47 1.19–1.81 0.000 2.03 1.40–2.94 0.000
Tertiles
1 1.00 1.00–1.00 1.00 1.00–1.00
2 1.12 0.83–1.50 0.456 1.36 0.74–2.52 0.322
3 1.70 1.28–2.27 0.000 2.86 1.63–5.01 0.000
Preoperative above median 1.36 1.08–1.72 0.009 2.44 1.53–3.89 0.000
STS Readmission Prediction Modela
Preoperative 1.03 1.01–1.04 0.002 1.03 1.00–1.06 0.005
Natural log 1.40 1.10–1.78 0.006 1.87 1.23–2.86 0.004
Tertiles
1 1.00 1.00–1.00 1.00 1.00–1.00
2 1.08 0.79–1.48 0.625 1.37 0.73–2.56 0.329
3 1.71 1.24–2.37 0.001 2.95 1.63–5.34 0.000
Preoperative above median 1.30 1.00–1.68 0.046 2.31 1.39–3.85 0.001
STS Readmission Prediction Model + NT-pro BNP
Preoperative 1.02 1.01–1.04 0.005 1.03 1.00–1.06 0.007
Natural log 1.31 1.03–1.68 0.028 1.73 1.13–2.65 0.012
Tertiles
1 1.00 1.00–1.00 1.00 1.00–1.00
2 1.08 0.79–1.48 0.631 1.36 0.72–2.57 0.337
3 1.65 1.19–2.29 0.003 2.85 1.57–5.16 0.001
Preoperative above median 1.28 0.99–1.66 0.060 2.26 1.35–3.76 0.002
aModel adjusts for variables included in the STS readmission prediction model
KDIGO Kidney Disease: Improving Global Outcomes, CI confidence interval, OR odds ratio, STS Society of Thoracic Surgeons
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rate (GFR) [13]. Its preoperative values have been
shown to independently associate with AKI following
cardiac surgery [29, 30]. Similarly, prior research has
demonstrated a relationship between brain natriuretic
peptide (BNP), NT-proBNP and Gal-3 with elevation
in both markers related to outcomes [31]. Preopera-
tive BNP, a polypeptide released by the ventricles in
response to volume overload, has been shown to pre-
dict postoperative development of AKI [29, 32]. The
inclusion of NT-proBNP in our study resulted in only
a moderate difference from our adjusted prediction
model. Compared to the adjusted model, the above
median preoperative Gal3 measurements were
non-signfiicant for those developing KDIGO Stage 1
in augmented model with NT-proBNP. The inclusion
of BNP in our prediction model could provide im-
portant inferences on cardiac-surgery associated with
AKI and heart failure, but further evaluation is
needed. Given the varying kinetics and characteristics
of individual biomarkers, it is likely that the measure-
ment of multiple biomarkers, in addition to Gal-3, is
necessary to accurately perform preoperative risk as-
sessment for AKI [29, 33].
The primary strength of this study is its large
sample size comprised of patients who underwent
cardiac surgery at eight hospitals across Maine, Ver-
mont and New Hampshire. Studies on preoperative
biomarker levels and prediction of AKI have been
previously conducted with small cohorts, in
single-center settings and lacked defined, explicit
outcomes [34]. In this study, we leveraged the
NNECDSG registry, which is comprehensive in the
patient and procedural data that it contains. The
completeness and quality of this data also helps en-
sure that adequate adjustment was carried out.
Study limitations
There are limitations to this study to consider. First,
we lacked detailed information on some conditions
known to affect the incidence of AKI including car-
diopulmonary bypass times, hemodynamics or the
use of inotropic and vasoactive drugs in the
perioperative period. Therefore, residual confounding
of the demonstrated association of Gal-3 with AKI
can not be excluded. Gal-3 has been found to be
correlated with pre-existing renal disease and heart
failure. Medical support to maintain blood pressure
arguably would be more aggressive in patients with
higher Gal-3 values, and our results would more
likely be biased towards the null-hypothesis. Sec-
ondly, we also used creatinine-based definitions for
AKI which are relatively insensitive and non-specific
in the period directly following insults to the kidney
[35]. Thirdly, we were also unable to evaluate
long-term outcomes such as major adverse renal and
cardiac events (MARCE). Fourthly, given the unique
patient characteristics associated with the CABG
patient population, there may be reproducibility limi-
tations with a more heterogeneous population. Fi-
nally, the mean imputation method used to address
missing data may influence the overall composition
and performance of the prediction model.
Conclusion
Improving the predictive ability of AKI risk prior to
surgery is critical to take preventative measures and
counsel patients on potential outcomes after cardiac
surgery. Elevated preoperative Gal-3 levels may be
used to augment risk information for patients at
greatest risk of developing AKI and AKI severity after
cardiac surgery. If Gal-3 is elevated, there are several
AKI mitigation strategies to employ including avoid-
ing surgery on the same day as cardiac catherization,
limiting transfusion, remote ischemic preconditioning
prior to surgery and stopping angiotensin-converting
enzymes inhibitors (ACEIs) and angiotensin receptor
blockers (ARBs) for 2 days after surgery.
We are the first to demonstrate a significant
association between the inflammatory and fibrosis
biomarker Gal-3 and AKI in patients undergoing
cardiac surgery. Our findings suggest that preopera-
tive Gal-3 levels could be used to identify patients at
the highest risk of developing AKI after cardiac
surgery.
Table 5 Model evaluation Gal3 & eGFR
STS Readmission Prediction Model + Risk Marker
C-statistic (95% CI) NRI NRI P IDI IDI P Test of Equality Pb
STS Readmission Model 0.69 (0.66–0.71)
Preoperative Gal-3 terciles 0.70 (0.67–0.72) 0.03 0.067 0.01 0.000 0.042
Preoperative eGFRa (mL/min/1.73 m^2) 0.69 (0.66–0.72) 0.02 0.124 0.00 0.010 0.302
P represents the statistical p value.
aEstimated glomerular filtration rate (eGFR)
bROC comparison against base model
NRI Net Reclassification Improvement index, IDI Integrated Discrimination Improvement index
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